Streetwise Expert Interviews

Ross Silver

Exceptional Management and Disruptive Products Top the Investment Checklist for Vista Partners' Ross Silver

Investing in micro- and small-cap biotech companies carries great risk, but for investors who take the time to dig out the value proposition, the upside can be phenomenal. Enter Ross Silver of Vista Partners, who publishes research and owns many of the stocks he writes about. In this interview with The Life Sciences Report, Silver puts two biotech names on the table for investors to consider.

(5/20/15) More >
Read More Streetwise Interviews

Fire Up the Immune System to Fight Cancers and Boost Portfolios: John McCamant

An immunotherapy revolution is rocking biotechnology, and investors are searching for just the right way to play the new trend. John McCamant, editor of the Medical Technology Stock Letter, has performed some serious diligence, and discusses a handful of names with a range of market caps and the potential to achieve significant investment upside. (5/12/15) More >

A Bull Run Hiccup: 2015 Small-Cap Biotech Watchlist Update

It's been four months since The Life Sciences Report's 2015 Small-Cap Biotech Watchlist was announced at the Biotech Showcase in San Francisco. The year is off to a bumpy start, though the rough ride is not predicated, necessarily, on individual company performance. Read on for highlights of the Watchlist's Q1/15 performance. (5/13/15) More >

Newsletter Briefs

"SNGX is an exciting company; it is rare to find a micro cap with such a diverse and broad clinical pipeline." (5/20/15) Soligenix Inc. - The Life Sciences Report Interview with Ross Silver More >

"INO has had a number of successes clinically and marquee collaborations that have led to its market cap being what it is today." (5/20/15) Inovio Pharmaceuticals Inc. - The Life Sciences Report Interview with Ross Silver More >

"Subsequent analysis of CANF's CF101 data shows promise in a certain subset of patients." (5/13/15) Can-Fite BioPharma Ltd. - The Life Sciences Report 2015 Small-Cap Biotech Watchlist Update with Reni Benjamin More >

"CBMG is a recently transformed company." (5/12/15) Cellular Biomedicine Group Inc. - The Life Sciences Report with John McCamant More >

"HLTH has developed a marketing component to drive more business to its individual centers, and has been very successful." (5/6/15) Nobilis Health Corp. - Interview with Bruce Campbell More >

"RP has a diversified portfolio of technologies, is very focused and is growing rapidly." (4/23/15) RepliCel Life Sciences Inc. - The Life Sciences Report Interview with Michael May More >

"IPD's business model is one we know and love; there is a lot of upside in this company." (4/16/15) ImpediMed Ltd. - The Life Sciences Report Interview with Shane Storey More >

"If MSB's cells work, we're talking about a multibillion-dollar, druglike, blockbuster CHF treatment." (4/8/15) Mesoblast Ltd. - The Life Sciences Report Interview with Jason Kolbert More >

Expert Analysis

"Multiple catalysts for SNGX are coming in 2015." (5/18/15) Soligenix Inc. - Jason Kolbert, Maxim Group More >

"We are initiating STEM with a Buy rating." (5/18/15) StemCells Inc. - Ching-Yi Lin, H.C. Wainwright & Co. More >

"NHC's Q1/15 revenue beat can be attributed to strong case volumes." (5/15/15) Nobilis Health Corp. - Russell Stanley, Mackie Research Capital More >

"SNSS will submit an NDA for Qinprezo for AML, later this year." (5/14/15) Sunesis Pharmaceuticals Inc. - Mara Goldstein, Cantor Fitzgerald More >

"BCLI is making progress with Phase 2 ALS study enrollment/dosing." (5/14/15) BrainStorm Cell Therapeutics Inc. - Jason Kolbert, Maxim Group More >

"IMUC is finalizing plans for the ICT-107 Phase 3 trial in GBM." (5/13/15) ImmunoCellular Therapeutics Ltd. - Jason Kolbert, Maxim Group More >

"An overall survival trend favors SNSS' vosaroxin plus cytarabine." (5/14/15) Sunesis Pharmaceuticals Inc. - Matthew Andrews, Wells Fargo Securities More >

"INO initiated a Phase 1 trial to evaluate INO-4212 for Ebola." (5/13/15) Inovio Pharmaceuticals Inc. - Yi Chen, H.C. Wainwright & Co. More >